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1 NIH3T3 fibroblast cells transfected with the full-length coding region of the MT2 human
melatonin receptor stably expressed the receptor that is coupled to a pertussis toxin-sensitive G
protein and exhibits high anity for melatonin (KI=261 pM).
2 The order of apparent anity for selected compounds was: 4-phenyl-2-propionamidotetralin (4P-
PDOT)42-phenylmelatonin42-iodomelatonin42-bromomelatonin46-chloromelatonin5melatonin
4luzindole4N-acetyl-tryptamine5N-[(2-phenyl-1H-indol-3-yl)ethyl]cyclobutanecarboxamide (com-
pound 6)4N-acetylserotonin.
3 4P-PDOT exhibited a very high selectivity (*22,000 times) for the MT2 receptor with respect to
the mt1 receptor subtype, as tested in comparative experiments with membrane preparations from
NIH3T3 cells stably transfected with the human mt1 receptor.
4 MT2 melatonin receptors mediated incorporation of [
35S]-GTPgS into isolated membranes via
receptor catalyzed exchange of [35S]-GTPgS for GDP. The relative intrinsic activity and potency of
the compounds were subsequently studied by using [35S]-GTPgS incorporation. The order of potency
was equal to the order of apparent anity. Melatonin and full agonists increased [35S]-GTPgS
binding by 250% over basal (taken as 100%). Luzindole did not increase basal [35S]-GTPgS binding
but competitively inhibited melatonin-stimulated [35S]-GTPgS binding, thus exhibiting antagonist
action.
5 The other two mt1 antagonists used here, 4P-PDOT and N-[(2-phenyl-1H-indol-3-yl)ethyl]cyclo-
butanecarboxamide, behaved as partial agonists at the MT2 subtype, with relative intrinsic activities
of 0.37 and 0.39, respectively.
6 These findings show, for the first time, important dierences in the intrinsic activity of analogues
between the human mt1 and MT2 melatonin receptor subtypes.
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Introduction
Melatonin is a hormone secreted rhythmically by the
mammalian pineal gland. This hormone plays a central role
in the regulation of many types of circadian and seasonal
behaviour in mammals (Morgan et al., 1994). In man,
melatonin elicits circadian, cardiovascular and hypnotic eects
(Reppert et al., 1996; Dollins et al., 1994; Lewy et al., 1995;
Cagnacci et al., 1998). Melatonin appears to evoke its eects
through high anity, G protein-coupled receptors (Morgan et
al., 1994). Currently, two subtypes of human melatonin
receptors have been identified: mt1 (preferentially expressed in
the brain) and MT2 (preferentially expressed in the retina)
(Reppert et al., 1994; 1995). Both native and recombinant
melatonin receptors are negatively coupled to adenylyl cylase
by pertussis toxin-sensitive G proteins (Morgan et al., 1994;
Reppert et al., 1994; 1995). Little is known about the relative
roles of the two receptor subtypes in the transduction of the
melatonin signal. A recent study with mt1 receptor-deficient
mice has suggested that the two melatonin eects on the mouse
suprachiasmatic nuclei, inhibition of neuronal firing and
entrainment of the circadian rhythm, could be independently
mediated by the two receptor subtypes (Liu et al., 1998). The
study of the dierent roles of the two receptor subtypes is
further impeded by the lack of selective melatonin receptor
agonists. Some melatonin receptor antagonists have been
reported to be highly selective for the human MT2 receptor
subtype (Dubocovich et al., 1997), but their ecacy has not yet
been tested at the human melatonin receptor subtypes. For this
reason we determined the anity and ecacy of one of these
analogues (4P-PDOT) at both human mt1 and MT2 receptors
in the present study.
Recently we have studied the anity and ecacy of a
number of known melatonin analogues at the mt1 human
melatonin receptor stably expressed in NIH3T3 fibroblast
cells, using the agonist-mediated [35S]-GTPgS binding method
for evaluation of the ecacy (Nonno et al., 1998). Agonist
stimulation of G protein-coupled receptors induces conforma-
tional changes in their cognate G proteins, leading to
activation of the G protein and eector activation. The
essential step for G protein activation is the GDP/GTP
exchange (Birnbaumer et al., 1990), that can be quantified by
the use of [35S]-GTPgS (Hilf et al., 1989; Lorenzen et al., 1993).
The amount of [35S]-GTPgS incorporation into membranes at
maximal concentrations of agonist is related to the intrinsic
activity of the agonist itself.*Author for correspondence.
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Studies on the ecacy of melatonin analogues at the
human MT2 receptor are still lacking. Here we report the
pharmacological characterization of the MT2 receptor stably
expressed in NIH3T3 mouse fibroblast cells and the activity
of known melatonin agonists, partial agonists and antago-
nists.
Methods
Cloning strategy and transfection
The human melatonin receptor MT2 gene has ben cloned by
means of PCR with specific oligonucleotides designed on the
GenBank sequence number U25341 (Human MT2 melatonin
receptor mRNA, complete coding strand). Two pairs of
primers have been used to clone the 5’ half and the 3’ half of
the gene from human Hippocampus cDNA (Clontech): 10F (5’
GCG ATG TCA GAG AAC GGC TCC TT) and 535R (5’
ACT CCA GGG ACC CCA CAA AGA AGT) to amplify
from nucleotide 9 (including the initiating methionine) to 559;
399F (5’ CAA TAT CAC TGC CAT CGC CAT TA) and
1081R (5’ CTA GAG AGC ATC TGC CTG GTG) to amplify
from nucleotide 399 – 1101 (including the Amber codon). The
PCR profile was as follows: 958C for 5 min, (958C for 1 min;
588C for 1 min; 728C for 1 min) for 5 cycles, (958C for 1 min;
668C for 1 min; 728C for 1 min) for 30 cycles; 728C for 7 min.
The PCR products have both been cloned (pGEM-T Vector
System, Promega) and sequenced and they have been found to
be identical to the U25341 sequence.
The 10F – 535R sequence overlaps for 160 bp with the
399F – 1081R sequence so that they share a Cfr10 I restriction
site that is unique to the entire gene sequence. The two PCR
products have been consequently cut by means of Cfr10 I
restriction enzyme (Boehringer Mannheim) and ligated at their
protruding ends. The final product was cloned in pcDNA3
expression vector (Invitrogen) and transfected in NIH3T3 cells
by using liposomal transfection (DOTAP, Boehringer Man-
nheim) according to the manufacturer’s instructions. The
NIH3T3 cells were plated at a density yielding approximately
60% confluence at the time of transfection. Cells were cultured
in Dulbecco’s Modified Eagle’s Medium containing high
glucose (4.5 g l71), 10% calf serum, 1 mM sodium pyruvate,
in 5% CO2/95% air at 378C. Selection with G418 (1 mg ml71)
was started 48 h after transfection. Transformed NIH3T3 cells
were isolated and the single colonies were selected by using 2-
[125I]-iodomelatonin binding (with a radioligand concentration
of 100 pM). Colonies expressing apparent Bmax values higher
than 150 fmol mg71 of total cellular protein were plated in
150 cm2 flasks.
Membrane preparation
NIH3T3 cells stably expressing the cloned human MT2
receptor were grown to confluence. On the day of assay,
cells were detached from flasks with 4 mM EDTA in 50 mM
Tris-HCl (pH 7.4 at room temperature) and centrifuged at
10006g for 10 min at 48C. The cells were then resuspened in
2 mM EDTA/50 mM Tris-HCl, homogenized in 10 – 15
volumes of ice-cold 2 mM EDTA/50 mM Tris-HCl with
Ultra-Turrax and centrifuged at 50,0006g at 48C for 25 min.
The final pellet was then resuspended in ice-cold 50 mM Tris-
HCl assay buer.
In experiments with pertussis toxin, cells were treated with
100 ng ml71 of pertussis toxin in culture medium for the 24 h
preceding the day of assay, and then prepared as described
above. Membrane protein levels were determined according to
the method of Bradford (1976).
2-[125I]-iodomelatonin binding
The final membrane concentration was 2 – 4 mg ml71 and the
protein concentration was 5 – 10 mg per tube. The binding
conditions were described in detail elsewhere (Stankov et al.,
1991). The incubation time was 90 min. In preliminary
experiments for the selection of colonies and in competition
experiments, the total 2-[125I]-iodomelatonin concentration was
100 pM. In saturation studies 2-[125I]-iodomelatonin was
added to achieve a concentration range of 10 up to 1000 pM.
Nonspecific binding was measured in presence of 0.1 mM cold
2-iodomelatonin.
[35S]-GTPgS binding
Agonist-stimulated [35S]-GTPgS binding was studied by using
a modification of previously published methods (Hilf et al.,
1989; Lorenzen et al., 1993). The final pellet, obtained as
described above, was resuspended in ice-cold 50 mM Tris-HCl
assay buer to give a final membrane concentration of 20 –
30 mg ml71. Then membranes (30 – 45 mg of protein per tube)
were incubated for 30 min at 308C, with and without various
drugs, in assay buer containing 0.3 – 0.5 nM [35S]-GTPgS,
50 mM GDP, 100 mM NaCl and 3 mM MgCl2.
The final incubation volume was 100 ml. Basal binding was
assessed in the absence of drug and nonspecific binding was
measured in presence of 10 mM GTPgS. In preliminary
experiments, carried out to determine optimal conditions to
study basal and melatonin-stimulated [35S]-GTPgS binding to
NIH3T3MT2 membranes, GDP 0.1 – 100 mM and NaCl 1 –
100 mM were used. The incubation was terminated by adding
1 ml of ice-cold Tris-HCl buer, pH 7.4, followed by rapid
filtration under vacuum through Whatman GF/B glass fibre
filters and by three washes with 3 ml of ice-cold Tris-HCl
buer, pH 7.4. Bound radioactivity was determined by liquid
scintillation spectrophotometry after overnight extraction in
4 ml Filter-Count scintillation fluid.
Data analysis
Data are reported as means+s.e.mean of at least three
independent experiments that were each performed in
duplicate (2-[125I]-iodomelatonin binding experiments) or
triplicate ([35S]-GTPgS binding experiments). The IC50, EC50
and KD values were determined by using nonlinear curve fitting
strategies. Saturation curves were analysed using the one-site
model compared with the two-site model. A two-site model
was accepted only when the ‘goodness-of-fit’ was significantly
(P50.05) improved by this model, as tested using a partial F-
test procedure (De Lean et al., 1978). Hill transformation of
the data has been performed to calculate Hill slope values in
saturation experiments. KI values were calculated from the IC50
values using the Cheng-Pruso equation (Cheng & Pruso,
1973). The data from [35S]-GTPgS binding experiments are
given as percentage of basal binding, where the basal binding
was fixed as 100%. The relative intrinsic activity values are
expressed as a fraction of melatonin maximal net stimulation.
The analysis of competitive interaction between melatonin and
luzindole was performed by using the equation:
pA2  log DRÿ 1 ÿ nlogB 1
where DR is the ratio of agonist IC50 values with or without
antagonist, and [B] is the antagonist concentration. When n
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(the slope of the corresponding Schild plot) is not significantly
dierent from 1, the pKB (instead of pA2) was calculated by
nonlinear fitting by using the following equation, as proposed
by Lew & Angus (1995):
pEC50  ÿlogB  10ÿpKB ÿ logc 2
where the agonist pEC50 in the presence of a given antagonist
concentration is plotted versus the antagonist concentration
[B] and allows the calculation of the pKB value as a fitted
parameter. The parameter 7logc is the dierence between the
antagonist pKB and the agonist pEC50.
In order to test the possible presence of ‘spare’ receptors in
our system (defined as the fraction of the total receptor pool
not required for maximal G protein activation in NIH3T3
cells) we used the equation proposed by Venter (1997):
H  ÿKA=KBH eES 3
where H is the height of the concentration eect curve, f is a
fixed concentration ratio [antagonist]/[agonist] and eES is an
eect-stimulus parameter, related to ecacy, that may be
defined as eES=hm/Hm, that is maximum height of the
concentration stimulus curve/maximum height of the con-
centration eect curve. An eES=1 indicates the absence of
‘spare’ receptors.
Statistical significance of the data was determined by
analysis of variance followed by the nonpaired two-tailed
Student’s t-test.
Drugs
2-[125I]-iodomelatonin (specificity activity=2000 Ci mmol71)
and [35S]-GTPgS (specific activity 1070 Ci mmol71) were
purchased from Amersham (Buckinghamshire, U.K.). Mela-
tonin, N-acetylserotonin, pertussis toxin, GDP and GTPgS
were from Sigma Chemical Co. (St. Louis, MO, U.S.A.). 2-
Iodomelatonin was obtained from RBI (Natick, MA, U.S.A.).
6-chloromelatonin was a gift from Ely Lilly laboratories
(Indianapolis, IN, U.S.A.). 2-Bromomelatonin, 2-phenylmela-
tonin and N-[(2-phenyl-1H-indol-3-yl)ethyl]cyclobutanecar-
boxamide (compound 6) were synthesized as described
elsewhere (Duranti et al., 1992; Spadoni et al., 1993; Garratt
et al., 1995). Luzindole and 4-phenyl-2-propionamidotetralin
(4P-PDOT) were from Tocris Cookson (Bristol, U.K.).
Geneticin (G418) was purchased from GIBCO (Grand Island,
NY, U.S.A.). General laboratory reagents including TrisHCl,
Calf Serum, Dulbecco’s Modified Eagle’s medium were from
Sigma Chemical Co. (St. Louis, MO, U.S.A.). Filter-Count
scintillation fluid was from Packard (Downers Grove, IL,
U.S.A.).
Results
Binding of 2-[ 125I]-iodomelatonin to the MT2 receptor
and competition studies
A number of clones were obtained and tested for MT2 receptor
expression with 2-[125I]-iodomelatonin (100 pM). The clone
expressing the highest 2-[125I]-iodomelatonin binding (single
point assay) was chosen for subsequent studies, in order to
ensure a good eect-to-noise ratio in the G protein stimulation
assay.
Saturation experiments show that, in the absence of sodium
ions and GTPgS, 2-[125I]-iodomelatonin binds to a single class
of high anity binding sites (Hill slope=1.01+1.02), with a
pKD of 10.28+0.05 and a Bmax of 502+38 fmol mg71 protein.
In order to investigate receptor-G protein coupling, a series of
saturation experiments conducted in the presence of GTPgS
and NaCl was performed. In the presence of GTPgS (100 mM)
2-[125I]-iodomelatonin binds to a single class of high anity
binding sites (Hill slope=0.98+0.02), with a pKD of
10.1+0.07 (not significantly dierent from the pKD value
obtained in absence of GTPgS, t=2.092, df=4, P=0.0523)
and a Bmax of 585+21 fmol mg71 protein, showing little
dierence to the binding profile in absence of GTPgS. In the
presence of 500 mM NaCl, 2-[125I]-iodomelatonin binds to a
single class of high anity binding sites (Hill
slope=0.97+0.03), with a pKD of 9.92+0.04 (significantly
dierent from the pKD value obtained in absence of GTPgS,
t=5.44, df=4, P50.05) and a Bmax of 592+33 fmol mg71
protein. On the contrary, the saturation curves obtained in the
presence of both 500 mM NaCl and 100 mM GTPgS were
significantly better described by the two-site model (Hill
slope= 0.80+0.04, significantly dierent from unity, t=4.33,
df=3, P50.05), with 20% of receptors being in the high
anity state, pKD=10.25+0.04, and 80% in the low anity
state, with a pKD of 9.38+0.04.
The pharmacological profile of the transfected MT2
receptor was studied in competition experiments with a
number of known melatonin analogues (Figures 1 and 3).
Melatonin showed a pKI of 9.60+0.06 (Table 1). The rank
order of apparent anity was: 4P-PDOT42-phenylmelato-
nin4 2-iodomelatonin42-bromomelatonin46-chloromelato-
nin5melatonin4luzindole4N-acetyl-tryptamine5N-[(2-phe-
nyl-1H-indol-3-yl)ethyl]cylobutanecarboxamide (we will refer
to this compound as compound 6)4N-acetylserotonin (pKI
values are shown in Table 1). 4P-PDOT competed with 2-
[125I]-iodomelatonin binding (Figure 3) with a slope of
70.50+0.03 (significantly dierent from unity, t=18.51,
df=4, P50.0001), thus not allowing KI calculation. The Hill
slope values of all other compounds tested were between
70.9 and 71, and they were not significantly dierent from
unity.
G protein activation by melatonin and its analogues
The basal [35S]-GTPgS binding to NIH3T3MT2 membranes was
80+5 fmol mg71 protein. Melatonin caused a dose-dependent
increase of the basal binding, to reach a plateau at&250+9%
with a pEC50 value of 9.22+0.04 (Figure 2; pEC50 and relative
intrinsic activity data are reported in Table 1). 2-Bromomela-
tonin, 2-iodomelatonin, 2-phenylmelatonin and 6-chloromela-
tonin also increased basal binding with a similar maximum
(262+6, 225+9, 245+3 and 250+2%), pEC50 values being
9.55+0.03, 9.97+0.18, 10.24+0.06 and 9.41+0.03, respect-
ively. N-acetyl-serotonin, N-acetyl-tryptamine, compound 6
and 4P-PDOT behaved as partial agonists with relative
intrinsic activities ranging from 0.37 to 0.81 (see Table 1 and
Figure 1). Luzindole was without any eect on basal [35S]-
GTPgS binding with the exception of a very little stimulation
over basal (0.07+0.02 relative to melatonin) at the highest
concentrations tested.
Luzindole was further able to dose-dependently shift the
melatonin concentration-eect curve when added at three
dierent concentrations (10, 100 nM and 1 mM), showing
competitive and surmountable antagonism. The slope of the
Schild plot was not significantly dierent from unity therefore
suggesting simple competitive antagonism. Analysis of these
data with the equation proposed by Lew & Angus (1995)
allowed calculation of a pKB value of 7.94+0.07 (Table 1).
Using the equation proposed by Venter (1997), in order to
investigate the presence of ‘spare’ receptors in our system, we
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calculated an eES value of 0.99, consistent with the absence of
‘spare’ receptors, and a KA/KB value of 0.04.
Binding anity and ecacy of 4P-PDOT and luzindole
at the human mt1 receptor
In previous work (Nonno et al., 1998) we characterized the
human mt1 melatonin receptor with the same analogues used
in this study with the exception of luzindole and 4P-PDOT, so
we also studied the interaction of these two compounds with
the mt1 receptor for comparison with MT2 (Figure 3). 4P-
PDOT and luzindole inhibited 2-[125I]-iodomelatonin binding
to membrane preparation obtained from NIH3T3 cells stably
expressing 600 fmol mg71 protein of the mt1 human receptor,
with pKI values of 6.98+0.05 and 6.72+0.04, respectively;
comparison of the competition curves obtained with mt1 and
MT2 membrane preparation reveals a high selectivity for 4P-
PDOT (IC50mt1/IC50MT2=22,000) and, to a lesser extent, also
for luzindole (KImt1/KIMT2=16.6).
Both analogues behaved as antagonists in the G protein
activation assay, being unable to significantly aect basal [35S]-
GTPgS binding to NIH3T3mt1 membranes at any concentra-
tion tested. In these experiments melatonin (100 nM) increased
[35S]-GTPgS binding to 350+10% over basal.
Pertussis toxin sensitivity
A 24 h pretreatment of NIH3T3MT2 cells with 1 mg ml71
pertussis toxin (PTX) completely abolished the melatonin
induced increase in [35S]-GTPgS binding. Basal [35S]-GTPgS
binding was significantly lower in membranes prepared from
PTX-pretreated cells (45+6%) than in membranes prepared
Figure 1 Competition curves of melatonin and its analogues for 2-
[125I]-iodomelatonin (2-125Imel) binding to NIH3T3MT2 membranes.
The data are representative of a single experiment with each point
determined in duplicate. The rank order of apparent anity was 2-
phenylmelatonin4 2-bromomelatonin4 6-chloromelatonin5melato-
nin4N-acetyl-tryptamine5compound 64N-acetylserotonin. The
experiment was carried out as described in Methods, for 90 min
at 378C. Each point is the mean of duplicate determinations; the
error bars indicate the standard deviation.
Table 1 Competition of 2-[125I]-iodomelatonin binding and
G protein activation for melatonin and its analogues
Compound
pKI
+s.e.meana
pEC50
+s.e.meana
IA
+s.e.meana
Melatonin
2-Iodomelatonin
2-Bromomelatonin
2-Phenylmelatonin
6-Chloromelatonin
N-acetyl-serotonin
N-acetyl-tryptamine
Luzindole
4P-PDOT
Compound 6
9.60+0.06
10.25+0.08
9.95+0.06
10.43+0.07
9.62+0.03
6.47+0.02
7.19+0.04
7.95+0.07
10.80+0.18b
7.07+0.06
9.22+0.04
9.97+0.18
9.55+0.03
10.24+0.06
9.41+0.03
6.51+0.03
7.03+0.05
7.94+0.04c
10.91+0.21
6.94+0.09
1
1.02+0.01
1.05+0.02
0.98+0.01
1.00+0.02
0.77+0.03
0.81+0.02
0.07+0.02
0.37+0.01
0.39+0.01
IA, relative intrinsic activity. aResults are expressed as
means+s.e.mean of at least three independent determina-
tions performed in duplicate (competition studies) or in
triplicate (G protein activation). bpIC50 value, slope=
70.50+0.05. cpKB value.
Figure 2 Comparison of the stimulation of [35S]-GTPgS binding to
NIH3T3MT2 membranes by melatonin and its analogues. The data
are representative of a single experiment with each point determined
in triplicate. The order of agonist potency (with relative intrinsic
activities obtained in this experiment reported in brackets) was: 4P-
PDOT (0.37)42-phenylmelatonin (0.98)42-bromomelatonin
(1.03)46-chloromelatonin (0.97)4melatonin (1)4N-acetyl-trypta-
mine (0.82)4compound 6 (0.41)4N-acetylserotonin (0.78). Luzin-
dole was without any eect on basal [35S]-GTPgS binding. The
experiment was carried out as described in Methods, for 30 min at
378C. Each point is the mean of triplicate determinations; the error
bars indicate the standard error. Values represent percentage of basal
binding, defined as 100%.
Figure 3 Comparison of competition curves for 4P-PDOT and
luzindole to 2-[125I]-iodomelatonin (2-125Imel) binding to NIH3T3MT2
(closed symbols) and NIH3T3mt1 (open symbols) membranes. The
data are representative of a single experiment in which each time
point is determined in duplicate. Both 4P-PDOT and luzindole show
higher anity for the MT2 receptor subtype. Note the slope of the
competition curve of 4P-PDOT (70.58) in NIH3T3MT2 membranes
with respect to the slope of luzindole (70.91) in NIH3T3MT2
membranes and to the slope of 4P-PDOT (70.96) and luzindole
(70.94) in NIH3T3mt1 membranes. The experiment was carried out
as described in Methods, for 90 min at 378C. Each point is the mean
of duplicate determinations; the error bars indicate the standard
deviation.
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from control cells (100%). Melatonin stimulated binding was
245+12% in control cells while it was not significantly
dierent from basal values in PTX-pretreated cells (the basal
[35S]-GTPgS binding to PTX-pretreated membranes was
37+3 fmol mg71 protein and the melatonin-stimulated bind-
ing was 40+2 fmol mg71 protein).
Discussion
MT2 human melatonin receptors stably expressed in NIH3T3
cells bound melatonin and its analogues with high anity and
mediated incorporation of [35S]-GTPgS into isolated mem-
branes via receptor-catalyzed exchange of [35S]-GTPgS for
GDP. G protein activation was completely abolished by
pertussis toxin treatment, showing Gi/o coupling with MT2
receptors.
2-[125I]-iodomelatonin bound to a single class of high anity
binding sites and this binding was resistant to modulation by
GTPgS. Both GTPgS and NaCl, when not coincubated,
reduced the anity of 2-[125I]-iodomelatonin for the MT2
melatonin receptor, probably by inducing a partial dissocia-
tion of R/G complexes, but the Hill slopes (0.98 and 0.97,
respectively) calculated from these saturation curves indicate a
homogeneous receptor population. On the contrary, receptor/
G protein complexes were eciently dissociated in presence of
both GTPgS and sodium chloride (Hill slope of 0.8 and
significant improvement of the ‘goodness of fit’ with the two-
site model). These data indicate that most of the melatonin
receptors expressed in NIH3T3MT2 cells were coupled with G
proteins in the presence of a full agonist (radiolabeled 2-
iodomelatonin), suggesting that in our system the G protein
concentration is not limiting; this conclusion is supported by
the finding that no spare receptors were present in our system,
as measured with the method proposed by Venter (1997).
GTPgS-insensitivity indicates that the receptors form very
stable receptor/G protein complexes. A GTPgS-insensitivity
has been only reported for the melatonin receptors expressed
in bovine (Nonno et al., 1995) and in the ovine hippocampus
(Barrett et al., 1994), but not in other native tissues that
express melatonin binding sites (Morgan et al., 1994), nor in
the human cerebellum (Fauteck et al., 1994) that expresses the
mt1 subtype (Mazzucchelli et al., 1996). We recently reported
insensitivity to modulation of receptor coupling to G proteins
by GTPgS also for the mt1 subtype stably expressed in
NIH3T3 cells (Nonno et al., 1998), while both recombinant
mt1 and MT2 subtypes were sensitive to guanine nucleotides
when transiently expressed in COS-7 cells (Dubocovich et al.,
1997). In that sense, the GTPgS-sensitivity of melatonin
receptors seems to be tissue- or system-dependent. Similar
findings have been reported for other PTX-sensitive G protein-
coupled receptors, such as A1 adenosine (Nano et al., 1995)
and the human 5HT1a receptor (Varrault et al., 1992).
Furthermore, Nano and coworkers (1997) reported the
partial purification of a membrane protein which stabilizes a
tight receptor/Gi protein coupling mode of the A1 adenosine
receptor; this protein, ‘coupling cofactor’, is responsible for the
resistance of R/G complexes to modulation by guanine
nucleotides. Wreggett & De Lean (1984) have also suggested
that stability of R/G complexes could be a common feature for
many Gi/o-coupled receptors.
The pharmacological profile obtained with competition
studies reveals that melatonin and 6-chloromelatonin share the
same apparent anity for the MT2 receptor, that is dierent
from the findings with the mt1 subtype, to which melatonin
binds with a 6 – 7 times higher anity than 6-chloromelatonin
(Nonno et al., 1998), thus confirming previous reports
(Reppert et al., 1994; 1995; Dubocovich et al., 1997). 4P-
PDOT was the compound with the highest anity to the MT2,
while it showed only a modest anity for the mt1 subtype, thus
revealing a very high mt1/MT2 selectivity (*22,000 fold).
Studies of anity of melatonin analogues for recombinant
human mt1 and MT2 receptor subtypes are limited. Dubocov-
ich et al. (1997) studied the anity of a number of melatonin
agonists, partial agonists and antagonists for both the mt1 and
MT2 human melatonin receptor expressed in COS-7 cells. They
reported that 4P-PDOT and some structurally-related analo-
gues bound with *300 times higher anity to the MT2
subtype, 4P-PDOT pKI values being 8.8 at MT2 and 6.3 at the
mt1 subtype, while in the present study 4P-PDOT showed a
pIC50 of 10.8 for the MT2 receptor and a pKI value of 6.98 for
the mt1 subtype. We cannot exclude that the MT2 anity of
4P-PDOT reported in the present work could be overestimated
due to the very low slope value of its competition curves,
accounting in part for the dierences observed between the two
studies and for the very high selectivity that we measured. In
the case of luzindole, in contrast, our results for both mt1 and
MT2 subtypes (pKI values of 6.72 and 7.95, respectively) were
very similar to those reported by Dubocovich et al. (1997) (pKI
values of 6.8 and 8).
To our knowledge the present work is the first study that
reports the ecacy of melatonin and its analogues for the MT2
human melatonin receptor. The results of the G protein
activation assay show that the human MT2 melatonin receptor
expressed in NIH3T3 cells is eciently coupled to a PTX-
sensitive G protein. Melatonin induced [35S]-GTPgS binding in
a dose-dependent manner with a pEC50 value of 9.22. This
value, similar to the other pEC50 values reported here for
agonists and partial agonists (see Table 1), is slightly lower
than the pKI value. This finding probably reflects the dierent
binding conditions of the two assays: in fact the [35S]-GTPgS
binding experiments were performed in the presence of 50 mM
GDP and 100 mM NaCl, that appears to induce the shift of a
portion of the melatonin receptor to the low-anity state,
while the membrane preparations used for 2-[125I]-iodomela-
tonin binding experiments appear to contain virtually only
high-anity binding sites (see data from 2-[125I]-iodomelatonin
saturation binding isotherms). This interpretation is supported
by the fact that, according to the ternary complex model
(Costa et al., 1992), the dierences induced by the presence of
GDP and NaCl are higher for full agonists than for partial
agonists and antagonist (the pKI value and the pKB value of
luzindole are identical).
Luzindole was the only antagonist at the MT2 subtype,
while other putative melatonin antagonists such as compound
6 and 4P-PDOT behaved as partial agonists (with relative
intrinsic activities of 0.39 and 0.37), the last showing very high
potency (pEC50=10.91). In a previous study we reported that
compound 6 showed antagonist activity at the mt1 receptor
stably transfectd in NIH3T3 cells (KB=67 nM) (Nonno et al.,
1998). In the present work we show that luzindole and 4P-
PDOT are also mt1 antagonists as well. Luzindole and
compound 6 are generally considered low anity melatonin
antagonists (Takaki et al., 1997; Garratt et al., 1995). In a
recent work Dubocovich et al. (1997) studied the ecacy of 4P-
PDOT and some structually related compound in the rabbit
retina and found them to be high-anity antagonists.
However, the above considerations are based on ecacy
studies performed in tissues or cells that express native
melatonin receptors and may contain a heterogeneous receptor
population. Therefore, they do not lend themselves to the
unequivocal characterization of an analogue action at a
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specific receptor subtype. For example, the antagonist activity
of compound 6 has been tested on pigment aggregation in
Xenopus laevismelanophores (Garratt et al., 1995) that contain
the Mel1c receptor, a melatonin receptor subtype that is not
present in mammals (Reppert et al., 1996), while luzindole
antagonizes the functional responses to melatonin in the
calcium-dependent dopamine release assay from the rabbit
retina (Dubocovich, 1988) and in the pigment aggregation in
Xenopus laevis melanophores (Sugden, 1992). The receptor
subtype composition of the rabbit retina is not definitively
known. Comparison of the antagonist anity constants
obtained from their ability to inhibit dopamine release
mediated by melatonin with their anity constants (2-[125I]-
iodomelatonin binding) determined in COS-7 cells expressing
the human MT2 receptors, suggested that the rabbit retina may
contain MT2 melatonin receptors (Dubocovich et al., 1997).
The dierence between the results obtained with 4P-PDOT in
the rabbit retina and the present data (obtained in NIH3T3
cells stably expressing human MT2 melatonin receptors) could
be due to diversity between the human and the rabbit MT2
melatonin receptors; another possible explanation is that 4P-
PDOT expresses residual intrinsic activity in our system
because of the high receptor number, and that such activity
could not be detected in native tissue.
On the basis of the data obtained with the human mt1 and
MT2 receptors expressed in the same cell type (NIH3T3) and
characterized with the same method for the evaluation of
relative intrinsic activities (stimulation of [35S]-GTPgS binding
to membranes) we are able to draw some conclusions
regarding the properties of compounds considered melatonin
receptor antagonists, as tested in our system: (i) luzindole
appears to antagonize both the human melatonin receptor
subtypes, with low anity to the mt1 and moderate anity for
the MT2; (ii) compound 6 behaves as a low-anity mt1-
antagonist and as a low-anity MT2-partial agonist and (iii)
4P-PDOT is a low-anity mt1-antagonist and a high-anity
MT2-partial agonist. These conclusions indicate that there are
dierent requirements for antagonist action between the two
human melatonin receptor subtypes and that those dierences
must be taken into account when studying the analogue’s
action in tissues for which the subtype composition is
unknown.
In summary, agonist-stimulated [35S]-GTPgS binding in
NIH3T3 cells is a sensitive method to study the human MT2
receptor activation of G proteins. MT2 receptor activation is
measured at a point preceding second messenger generation
and allows one to distinguish compounds of diering intrinsic
activity and potency.
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